Automated dosing schemes for administration of microtablets of levodopa for Parkinson’s disease, using wearable sensors
Objective: The aim of this study is to investigate the feasibility of using a dose optimization algorithm for dose individualization of microtables of levodopa. Background:…Speech and voice response to levodopa in late-stage Parkinson’s Disease patients: report from an acute levodopa challenge
Objective: to assess the change of speech and voice after an acute L-dopa challenge in late-stage Parkinson’s disease (LSPD). Background: PD patients are classically affected…Treatment of secondary movement disorders related to midbrain cavernomas
Objective: To evaluate possible efficacy and safety of standard antiparkinsonian drugs (levodopa formulations, amantadine) in patients with symptomatic midbrain cavernomas (haemorhage and/or surgery) and secondary…Levodopa effect and motor function in late stage Parkinson’s disease
Objective: To assess responsiveness to Levodopa (L-dopa) in patients with late stage Parkinson’s disease (PD). Moreover, to investigate if the L-dopa effect is stable or…Acute L-dopa Challenge Test In Early Parkinsonism With Respect To Presence Of Red Flag Signs &MRIAbnormalitis
Objective: In this study we have tried to find any association between acute levodopa challenge responsiveness,red flag signs of parkinsonism and neuroimaging abnormality Background: Distinguishing…Mechanisms of sub-anesthetic ketamine infusions to reduce L-DOPA-induced dyskinesia: effects on striatal mTOR signaling and beta band oscillations in striatum and motor cortex
Objective: To evaluate mechanism of long-term activity of sub-anesthetic ketamine infusion to reduce L-DOPA-induced dyskinesia (LID). Background: We have published preclinical evidence and patient case…Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD
Objective: To evaluate whether continuous 24 hours delivery of subcutaneous ND0612 offers practical and clinical benefits over continuous delivery over the waking day (14 hours).…Levodopa induced dyskinesia in a case of progressive supranuclear palsy.
Objective: We describe the mechanism of dyskinesia in patients with progressive supranuclear palsy (PSP). Background: Levodopa generally shows a poor effect to parkinsonism in patients…Does levodopa-carbidopa intestinal gel in Parkinson’s disease patients increase the risk on polyneuropathy?
Objective: To analyze the influence of the overall levodopa exposure on the risk of polyneuropathy (PN) in levodopa-carbidopa intestinal gel (LCIG)-infusion treated patients with Parkinson’s…Patient perspectives of using the ND0612 mini-pump
Objective: To evaluate patient and caregiver usability and satisfaction with the mini-pump that will be used for continuous ND0612 delivery among patients with moderate-severe PD.…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 57
- Next Page »